DexCom (DXCM) Guides Margins Below Consensus, Piper Sandler Would Buy the Weakness
Tweet Send to a Friend
Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $500.00 price target on DexCom (NASDAQ: DXCM) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
